Evidence map›Paper›PMID 41800023›Full record

ReviewImmune network2026

The Role of B Cells in Tumorigenesis and Immunotherapy.

Guoping Yin, Lingna Qi, Na Kang, Tong Li, Cuifeng Li, Yile E Liu, Jingying Ye, Wanli Liu

Abstract readReview
In one paragraph

Review in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guoping YinDepartment of Otorhinolaryngology-Head and Neck Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.ORCID https://orcid.org/0000-0003-2576-4325
Lingna QiDepartment of Otorhinolaryngology-Head and Neck Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.ORCID https://orcid.org/0009-0009-4991-4843
Na KangState Key Laboratory of Membrane Biology, Institute for Immunology, School of Life Sciences, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China.
Tong LiState Key Laboratory of Membrane Biology, Institute for Immunology, School of Life Sciences, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China.
Cuifeng LiState Key Laboratory of Membrane Biology, Institute for Immunology, School of Life Sciences, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China.
Yile E LiuThe First Affiliated Hospital of Anhui Medical University and Institute of Clinical Immunology, Anhui Medical University, Hefei 230022, China.
Jingying YeDepartment of Otorhinolaryngology-Head and Neck Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.ORCID https://orcid.org/0000-0002-4022-6202
Wanli LiuState Key Laboratory of Membrane Biology, Institute for Immunology, School of Life Sciences, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China.ORCID https://orcid.org/0000-0003-0395-2800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the tumor microenvironment (TME), the potential role of B cells in tumor immunotherapy has not been paid enough attention for a long time. In recent years, B cells have been widely infiltrated in the TME of a variety of solid tumors, and their functional status significantly affects tumor progression and immune response. B cells can inhibit tumor progression through inducing and maintaining tertiary lymphoid structures and lympho-myeloid aggregates, Ab-dependent anti-tumor effects, Ag presentation, T cell activation, and direct anti-tumor effects. It can also inhibit anti-tumor immune response by producing tumor-promoting antibodies, secreting immunosuppressive cytokines and chemokines, and expressing immune checkpoint molecules. The factors that influence B cell differentiation and function have not been fully elucidated. The complete analysis of these complex factors is essential for designing more precise B-cell-targeted therapies. In addition, based on their dual effects, immunotherapy strategies targeting B cells have developed rapidly. B cells have become an important target for a new generation of immunotherapy. This review systematically expounds on the dual regulatory mechanisms of B cells in the occurrence and development of tumors, analyzes the key factors affecting their functions, and explores the clinical application prospects of targeted B cell therapy to aid in the precise immunotherapy of tumors.

Indexed as

B-lymphocytesImmunotherapyTumor microenvironment

Identifiers

PMID41800023
PMCPMC12962832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.